Active, not recruitingPHASE1, PHASE2NCT05120271
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors
Studying Pediatric hepatocellular carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sotio Biotech Inc.
- Principal Investigator
- Pauline Duhard, Pharm.D.SOTIO Biotech AG
- Intervention
- CAR-GPC3 T Cells(biological)
- Enrollment
- 7 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2022 – 2042
Study locations (8)
- Hoag Hospital Newport Beach, Newport Beach, California, United States
- Baylor Scott and White Research Institute, Dallas, Texas, United States
- University of Texas MD Anderson Cancer Center, Houston, Texas, United States
- Fred Hutchinson Cancer Center - Seattle Cancer Care Alliance (SCCA) Location, Seattle, Washington, United States
- Froedtert and Medical College of Wisconsin, Milwaukee, Wisconsin, United States
- Beatson Institute for Cancer Research Wolfson Wohl Cancer Research Centre, Glasgow, United Kingdom
- University College London Hospitals NHS Foundation Trust, London, United Kingdom
- The Royal Marsden NHS Foundation Trust, London, United Kingdom
Collaborators
SOTIO Biotech a.s. · SOTIO Biotech AG
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05120271 on ClinicalTrials.govOther trials for Pediatric hepatocellular carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07295340Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC DetectionWest China Hospital
- RECRUITINGNANCT06050200TANGO-LIVER Three Arm Nuclear Growth Observation in Liver SurgeryMedical University of Warsaw
- RECRUITINGPHASE1NCT04715191Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid TumorsBaylor College of Medicine
- RECRUITINGNCT06669377TACE Combined With ICIs Plus MTT After 125I Irradiation Stent Placement in HCC With Main PVTT.Zhongda Hospital
- ACTIVE NOT RECRUITINGNANCT07214363The Safety and Efficacy of Irreversible Electroporation for the Treatment of Perivascular Liver CancersNational Taiwan University Hospital
- RECRUITINGNANCT05738980Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3Beijing Hospital
- RECRUITINGNCT05517811Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical ResectionUniversity of Colorado, Denver
- ACTIVE NOT RECRUITINGPHASE1NCT04377932Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid TumorsBaylor College of Medicine